Children's Cancer Institute welcomes government's commitment to the Medical Research Future Fund
December 15, 2014
Children's Cancer Institute has welcomed the announcement by the Prime Minister and the Minister for Health of a new funding package to see the $20 billion Medical Research Future Fund (MRFF) realised.
The Institute’s Executive Director, Professor Michelle Haber AM, said a perpetual fund like the MRFF would provide vital funding for dedicated medical research, which we believe will eventually put an end to childhood cancer.
“The MRFF will be critical in further advancing childhood cancer research and treatment,” said Prof Haber, “and has the very real potential to substantially improve outcomes for children with cancer.
“This is so important for the Australian community because we know 625 children are diagnosed with cancer each year and one in five children will die from their disease.”
Sixty years ago, cancer was almost always a death sentence for a child. Today, as a result of medical research, eight out of ten children survive.
“This is why our work is vital,” continues Prof Haber. “It’s up to us to make sure that our discoveries continue to progress into new treatments for kids as quickly as possible, but we need the funds to make this happen.
“We’re steadfastly committed to giving Australian children diagnosed with the most aggressive cancers the best possible chance of survival – and the MRFF will be instrumental in helping us achieve this.
“The interest off the $20 billion MRFF will deliver an extra $1 billion in funding per year, which is an effective doubling of government funding and will go a long way in helping us achieve our vision of curing all children with cancer.”
For more information about the Medical Research Future Fund Action Group, visit their website:imagineahealthierfuture.org
About Children’s Cancer Institute
Originally founded by two fathers of children with cancer in 1976, Children’s Cancer Institute is the only independent medical research institute in Australia wholly dedicated to research into the causes, prevention and cure of childhood cancer. Forty years on, our vision remains unchanged – to save the lives of all children with cancer and to eliminate their suffering. The Institute has grown to now employ more than 220 researchers, operational staff and students, and has established a national and international reputation for scientific excellence.
Our focus is on translational research, and we have an integrated team of laboratory researchers and clinician scientists who work together in partnership to discover new treatments which can be progressed from the lab bench to the beds of children on wards in our hospitals as quickly as possible. These new treatments are specifically targeting childhood cancers, so we can develop safer and more effective drugs and drug combinations that will minimise side-effects and ultimately give children with cancer the best chance of a cure with the highest possible quality of life.
We are currently leading the establishment of the Zero Childhood Cancer national child cancer personalised medicine program for children with the most aggressive cancers, in partnership with the Sydney Children’s Hospitals Network. This program will revolutionise the way treatment decisions are made, with the aim of improving survivorship for those children at highest risk of treatment failure from their disease.